A shared compound library that rare cancer researchers can actually use
Companies hold thousands of well-characterised drugs that could help rare cancers, but each request takes a year of legal negotiation. One standing agreement would unblock it.
Academic rare cancer groups routinely fail to obtain clinical-grade compound for investigator-initiated trials because material transfer and intellectual property negotiation exceed the capacity of small teams. A pre-negotiated multi-company access pool — standard terms, a single application route, an independent scientific review committee and mandatory data return — would industrialise access. Precedents exist in structural genomics consortia and in some public-private compound-sharing schemes.
- Rare and paediatric cancers without markets · Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in.
- Secrecy and intellectual property block collaboration · Companies with complementary drugs rarely test them together, and data that could answer questions stays locked up.
- The valley of death between lab and product · Most academic discoveries die before anyone tests them in people because nobody funds the middle step.
Pages like this
not linked directly; found by shared links- IdeaEvery approved cancer drug ships with a public combination-readiness data pack
Shares DrugBank & ChEMBL, Secrecy and intellectual property block collaboration.
- IdeaEnforce individual participant data sharing as a condition of publication and funding
Shares ClinicalTrials.gov, Secrecy and intellectual property block collaboration.
- IdeaRequire every oncology candidate to publish how much reaches the brain
Shares DrugBank & ChEMBL, ClinicalTrials.gov.
- IdeaA commons of shelved cancer drugs with their full data, open to new hypotheses
Shares DrugBank & ChEMBL, The valley of death between lab and product.
- IdeaA public-benefit phase 1 factory that takes academic discoveries into first-in-human trials
Shares The valley of death between lab and product, National Cancer Institute (NIH).
- IdeaAutomatic offer of shelved cancer assets to non-profits after two years
Shares Secrecy and intellectual property block collaboration, The valley of death between lab and product, Rare and paediatric cancers without markets.
- IdeaOpen-source drug discovery to clinical proof of concept for neglected cancers
Shares Secrecy and intellectual property block collaboration, Rare and paediatric cancers without markets.
- InstitutionCancer Prevention and Research Institute of Texas
Shares The valley of death between lab and product, National Cancer Institute (NIH).